![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00006314 |
To investigate the relationship between HCMV and bone marrow progenitor cells to understand whether HCMV is latent in CD34 + bone marrow progenitors and the mechanism by which the virus remains in a latent state.
Condition |
---|
Blood Disease Cytomegalovirus Infections |
Study Type: | Observational |
Study Design: | Natural History |
Study Start Date: | July 1999 |
Estimated Study Completion Date: | June 2004 |
BACKGROUND:
Despite progress in understanding the pathophysiology of human cytomegalovirus (HCMV) infections, its manifestations in the immune compromised host are frequently associated with high morbidity and mortality. In this setting, HCMV disease can develop e.g. following immune suppression as a result of reactivation of latent HCMV acquired earlier in life. The mechanisms leading to establishment of latent infections and their subsequent reactivation are not clear. It is also unknown whether HCMV exists in a latent form with limited viral gene expression or as a persistent infection with normal virus transcription.
DESIGN NARRATIVE:
The specific aims of the study were to: 1) examine the percentage of HCMV positive donors whose bone marrow progenitors contained HCMV DNA using nested PCR and determine if virus could be rescued from those cells. 2) Analyze the HCMV life cycle in hematopoietic progenitor and stem cells. 3) identify and analyze HCMV gene expression in in vivo infected leukocytes. Bone marrow progenitors containing HCMV DNA detectable by nested PCR were isolated from human donors and used as as source of mRNA to prepare Cdna libraries. 4) Determine if gene(s) expressed in bone marrow progenitors were important in either establishing or maintaining a latent infection or in the lytic cycle of HCMV. Information provided from the above studies yielded information important in planning future approaches for the therapy of HCMV infections.
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
No eligibility criteria
Study ID Numbers: | 922 |
Study First Received: | September 28, 2000 |
Last Updated: | January 27, 2006 |
ClinicalTrials.gov Identifier: | NCT00006314 History of Changes |
Health Authority: | United States: Federal Government |
Virus Diseases Hematologic Diseases Cytomegalic Inclusion Disease Cytomegalovirus Infections |
DNA Virus Infections Cytomegalovirus Herpesviridae Infections |
Virus Diseases Hematologic Diseases Cytomegalovirus Infections |
DNA Virus Infections Infection Herpesviridae Infections |